CD274 and neoplasm: Clearance of circulating tumor cells or micrometastatic deposits by enhancement of the T1 immune tumor response by blockade of programmed death (PD)-1 receptor and programmed death-ligand 1 (PDL-1) may represent a more efficacious therapeutic pathway that antiangiogenic blockade [21], as has been demonstrated in management of clinical metastatic disease [13, 22].